Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2012 16:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Third Quarter Fiscal 2012 Results and Clinical Program Developments

MORRIS PLAINS, N.J., May 8, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
May 01, 2012 08:15 ET | Source: Immunomedics, Inc.

Immunomedics Awarded New Patent for Pretargeted Imaging and Therapy of Cancer With Bispecific Antibody

MORRIS PLAINS, N.J., May 1, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
April 03, 2012 14:00 ET | Source: Immunomedics, Inc.

Immunomedics Develops Novel Agents Targeting Renal Cell Carcinoma

Study Reported at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) Preclinical Study of Ranpirnase-Based Therapeutics for Breast Cancer Also Presented CHICAGO,...
April 02, 2012 14:00 ET | Source: Immunomedics, Inc.

Immunomedics Develops Bispecific Hexavalent Antibodies for Diverse Epithelial Cancers

Novel Dock-and-Lock (DNL) Agents Presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) The Impact of Linker's Stability on Efficacy of Antibody-SN-38...
April 02, 2012 09:00 ET | Source: Immunomedics, Inc.

Immunomedics Reports Clinical Results of Pretargeted Radioimmunotherapy of Colorectal Cancer

CHICAGO, April 2, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted...
March 26, 2012 08:30 ET | Source: Immunomedics, Inc.

Immunomedics to Report Progress With Novel DNL Agents Targeting Solid Tumors at Cancer Conference

MORRIS PLAINS, N.J., March 26, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
March 07, 2012 16:00 ET | Source: Immunomedics, Inc.

Immunomedics Appoints Marcella LoCastro to Board of Directors

MORRIS PLAINS, N.J., March 7, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
February 22, 2012 08:30 ET | Source: Immunomedics, Inc.

Immunomedics to Present at Upcoming Healthcare Conferences

MORRIS PLAINS, N.J., Feb. 22, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
February 08, 2012 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Announces Second Quarter Fiscal 2012 Results and Clinical Program Developments

MORRIS PLAINS, N.J., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
January 31, 2012 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Awarded Broad Patent for Anti-CD20 and Anti-CD22 Combination Therapy

MORRIS PLAINS, N.J., Jan. 31, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...